Clinical Evaluation of the Accuracy of Vitastiq Device for Tracking Vitamin and Mineral Trend in Human Body

NCT03399240•Vitastiq d.o.o.

Summary

This is a single site evaluation study of Vitastiq device accuracy in healthy men and women in ratio 1:1 (approximately) aged between 18 and 64 years. A total of 45 Vitastiq personal devices will be used by volunteers for two months. The Vitastiq device will be evaluated during three site visits: on day 1, 29 ± 4 days and 57 ± 4 days. During site visit days, blood sampling will be collected and analysed and readings using Vitastiq device will be performed. Data will be analysed retrospectively to evaluate Vitastiq performance compared to blood tests results.

Eligibility

Age

18 - 64 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Informed consent form (ICF) is signed by a volunteer
•Age between 18 and 64 years at the time of the signature of ICF
•A body mass index (BMI) between 18 and 28 kg/m2
•Healthy, meaning absence of any chronic or acute medical therapy for a month prior to the inclusion to the study
•Willing to follow all study procedures, including attending all site visits, and keeping a food diary and diary of activities on a weekly basis

Exclusion Criteria

•Intake of any drugs to treat chronic disease within 1 month before the beginning and during the study
•Intake of any drugs to treat serious acute disease within 1 month before the beginning of the study and within 5 days of each visit
•Any clinically significant medical history of serious digestive tract, liver, kidney, skin or haematological disease or hormone imbalance
•Pregnant and breastfeeding women
•Women who planning pregnancy during the study
•Inadequate veins (in the opinion of the investigator)
•Known drug or alcohol abuse
•Using any form of nicotine or tobacco
•Mental incapacity that precludes adequate understanding or cooperation
•Participation in another investigational study or blood donation within 3 months prior to or during this study

Locations (1)

Adria Lab d.o.o.

Ljubljana, Slovenia

Key Dates

Start Date

May 17, 2017

Primary Completion Date

November 2, 2017

Completion Date

November 2, 2017

Last Updated

January 16, 2018

Enrollment

ACTUAL participants

Conditions

No Conditions

Interventions

Vitasitiq device

DEVICE

Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control

NCT02920359

There Are no Conditions Under Study. Healthy Volunteers

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 16, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions